A quantitative systems pharmacology workflow toward optimal design and biomarker stratification of atopic dermatitis clinical trials
Atopic dermatitis (AD) is a chronic inflammatory condition of the skin characterized by recurrent eczematous lesions and intense itch that can profoundly impair quality of life.1-6 The pathophysiology of AD is complex and involves local and systemic immune dysregulation, genetic susceptibility, environmental factors, and microbiome effects.7,8 AD is a heterogeneous disease that encompasses a variety of endotypes and phenotypes (see the work cited in Facheris et al9). The road to novel AD therapeutics10 is tortuous due to a combination of 2 factors:
Source: Journal of Allergy and Clinical Immunology - Category: Allergy & Immunology Authors: Natacha Go, Simon Ars ène, Igor Faddeenkov, Théo Galland, Shiny Martis B., Diane Lefaudeux, Yishu Wang, Loic Etheve, Evgueni Jacob, Claudio Monteiro, Jim Bosley, Caterina Sansone, Christian Pasquali, Lorenz Lehr, Alexander Kulesza Source Type: research
More News: Allergy | Allergy & Immunology | Clinical Trials | Dermatitis | Dermatology | Drugs & Pharmacology | Environmental Health | Genetics | Itchiness | Skin